CHR Chr. Hansen Holding A/S

Notice to convene the Annual General Meeting 2020

Notice to convene the Annual General Meeting 2020

Company announcement no. 25

The Annual General Meeting of Chr. Hansen Holding A/S will be held on 

Wednesday, November 25, 2020 at 4:00 p.m. CET

at Søhuset Konferencecenter, Venlighedsvej 10, 2970 Hørsholm, Denmark.

The notice to convene the Annual General Meeting, including annex 1 “Description of the candidates for the Board of Directors”, is enclosed.

Important notice in relation to the COVID-19 pandemic

In order to protect the health and safety of all and given the Danish government’s restrictions on assembly, we strongly recommend that shareholders follow the Annual General Meeting via live-stream instead of attending in person, and make use of the possibility to give proxy or vote by correspondence.

Shareholders are encouraged to submit written questions concerning the agenda or the documents, etc. to be considered at the Annual General Meeting at least one week ahead of the meeting, i.e. no later than Wednesday November 18, 2020. Questions can be submitted to . The Company will aim to answer such questions in writing before the Annual General Meeting.

No refreshments will be served at the Annual General Meeting.

For more information please refer to the “Important notice in relation to the COVID-19 pandemic” on page 2 of the notice to convene the Annual General meeting.

 

For further information please contact:

Martin Riise, Senior Director, Investor Relations, Tel:

Annika Stern, Investor Relations Officer, Tel:

Camilla Lercke, Head of Media Relations, Tel:

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose –  To grow a better world. Naturally. – is at the heart of everything we do.

Attachments

EN
29/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chr. Hansen Holding A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (No_rec, TP: DKK) - Discontinuing coverage

We have discontinued coverage of Chr. Hansen in light of its combination with Novozymes. Our last published recommendation, target price, and estimates should no longer be relied upon.

 PRESS RELEASE

Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund Anders Enevoldsen Press Relations Lina Danstrup Attachment

 PRESS RELEASE

All necessary regulatory approvals have been obtained for the combinat...

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (Hold, TP: DKK582.00) - Down to HOLD, target price raised

We forecast Chr. Hansen to reach the high end of its 2023 guidance of 10–12% organic revenue growth and a 26–27% EBIT margin, but expect the combined entity (Novonesis) to issue a new guidance upon completion of the merger. As Chr. Hansen shareholders are set to receive 1.5236 new B-shares in Novonesis, the changes in our Novozymes model translate into a raised Chr. Hansen target price of DKK582 (536), and we have thus downgraded to HOLD (BUY).

 PRESS RELEASE

Update on the merger approval process for the combination of Novozymes...

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted December 20, 2023 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch